PP03 Economic Evaluation Of Recombinant Thyroid-Stimulating Hormone - Combined With Radioiodine Ablation For Patients With Differentiated Thyroid Cancer

Sep 29, 2026

Uploaded by Eliana

Economic evaluation assesses recombinant thyroid-stimulating hormone (TSH) followed by radioiodine ablation for differentiated thyroid cancer from the Brazilian Unified Health System perspective. The analysis estimates incremental cost-effectiveness using a Markov model with states of no recurrence, recurrence, and death over a 30-year horizon with a 5% discount rate for costs and outcomes. Quality-adjusted life years and life years are compared to the absence of these procedures, using deterministic and probabilistic sensitivity analyses. Results indicate dominance through lower costs and improved QALYs and LYs.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Introduction

Methods

Results

Conclusions

PP02 Analysis Of The Logistics And Time Impact Of Different Treatments Available For Paroxysmal Nocturnal Hemoglobinuria In Brazil Verónica Mata ([veronica.mata@roche.com](veronica.mata@roche.com)), Laura Branco and Florine Cordeiro Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening blood disorder, affecting one to 1.5 new individuals per million annually worldwide. In Brazil, there are three registered treatments: eculizumab, pegcetacoplan, and ravulizumab, while crovalimab is currently under evaluation by ANVISA, the Brazilian Health Regulatory Agency. This study examined the impact of these PNH treatments on the logistics and time required by healthcare professionals and patients for administration. Methods: Quantitative and descriptive analysis was conducted based on information from the package leaflets of eculizumab, ravulizumab, pegcetacoplan, and crovalimab regarding the number of vials, volume, and administration time for each medication for a patient with PNH weighing between 60 and 100 kg over a period of 52 weeks. Results: The number of vials required for treatment over 52 weeks was 78 for eculizumab, 102 for pegcetacoplan, 70 for ravulizumab, and 26 for crovalimab. The volume to be transported would be 4,680 mL for eculizumab, 2,080 mL for pegcetacoplan, 231 mL for ravulizumab, and 52 mL for crovalimab. Regarding the time required for each infusion per year (52 weeks), it would take 14.6 hours foreculizumab, 4.7 hours for ravulizumab, 78 hours for pegcetacoplan, and 1 . 1 hours for crovalimab. Conclusions: This study demonstrated that crovalimab can reduce the number of vials needed by 169 percent, transportation and storage volume by 344 percent, and infusion time by 331 percent. These efficiencies, applicable to both healthcare professionals and patients, highlight crovalimab’s potential to significantly enhance the sustainability of Brazilian public healthcare system and improve quality of life for patients. PP03 Economic Evaluation Of Recombinant ThyroidStimulating Hormone Combined With Radioiodine Ablation For Patients With Differentiated Thyroid Cancer Mariana Fachi ([mariana.fachi@haoc.com.br](mariana.fachi@haoc.com.br)), Ludmila Gargano, Haliton Oliveira Junior, Rosa Camila Lucchetta and Layssa Oliveira Introduction: Differentiated thyroid cancer (DTC) treatment involves thyroidectomy and radioiodine ablation. Some patients have contraindications to induced endogenous hypothyroidism or cannot produce endogenous thyroid-stimulating hormone (TSH), preventing ablation unless recombinant TSH is used. This study aimed to evaluate the cost effectiveness of recombinant TSH followed by ablation in patients with DTC from the Brazilian Unified Health System perspective. Methods: An economic evaluation was conducted to estimate the incremental cost-effectiveness ratio of radioiodine ablation (with prior recombinant TSH), compared with the absence of these procedures in patients who, after thyroidectomy, are unable to induce endogenous hypothyroidism. A Markov model was built with three health states: no recurrence, recurrence, and death. The outcomes evaluated were quality-adjusted life years (QALYs) and life years (LYs) gained. Direct medical costs were included over a 30-year time horizon, with a five percent discount rate applied to both costs and outcomes. A deterministic and probabilistic sensitivity analysis was also performed. Results: In general, the combination of recombinant TSH with radioiodine ablation proved to be dominant compared with not performing ablation, resulting in lower costs (BRL25,062 versus BRL26,941 [USD10,271 versus USD11,041]) and better clinical outcomes (QALYs 9 .69 versus 9 .55 and LYs 10 .82 versus 10 .57) . This result was mainly due to a statistically significant difference in recurrence rates. In the probabilistic sensitivity analysis, most simulations showed greater clinical benefit with recombinant TSH and ablation than no a

FAQs

What clinical situation motivates using recombinant TSH before radioiodine ablation?

Some differentiated thyroid cancer patients cannot induce endogenous hypothyroidism or cannot produce endogenous TSH after thyroidectomy, so ablation requires recombinant TSH.

How was cost-effectiveness assessed in the study?

A Markov model with three health states (no recurrence, recurrence, death) estimated costs and health outcomes over 30 years, applying a 5% discount rate and running deterministic and probabilistic sensitivity analyses.

What were the main findings of combining recombinant TSH with radioiodine ablation?

The combination was dominant versus not performing ablation, producing lower total costs and better outcomes, with improved QALYs and life years driven largely by differences in recurrence rates.

Sep 29, 2026

Uploaded by Eliana